Your browser doesn't support javascript.
loading
Risk of corrected QT interval prolongation in patients receiving antipsychotics.
Rivas, Juan Carlos; Galindo-A, Juliana; Zambrano, Luis Fernando; Miranda-B, Carlos Alberto; Ramírez, Sandra Milena; Rivas-Grajales, Ana María; Hernández-Carrillo, Mauricio; Rincón, Erika Andrea; Perafán, Pablo Eduardo; Gómez-Mesa, Juan Esteban.
Afiliação
  • Rivas JC; Department of Psychiatry, Universidad del Valle, Cali, Colombia.
  • Galindo-A J; Department of Psychiatry, Universidad Icesi, Cali, Colombia.
  • Zambrano LF; Department of Psychiatry, Fundación Valle del Lili, Cali, Colombia.
  • Miranda-B CA; Department of Psychiatry, Hospital Psiquiátrico Departamental Universitario del Valle, Cali, Colombia.
  • Ramírez SM; Department of Psychiatry, Universidad del Valle, Cali, Colombia.
  • Rivas-Grajales AM; Department of Psychiatry, Universidad Icesi, Cali, Colombia.
  • Hernández-Carrillo M; Department of Psychiatry, Universidad del Valle, Cali, Colombia.
  • Rincón EA; Department of Psychiatry, Universidad del Valle, Cali, Colombia.
  • Perafán PE; Department of Neuropsychiatry, Boston University Medical School, Boston, Massachusetts, USA.
  • Gómez-Mesa JE; Department of Neuropsychiatry, Boston Medical Center, Boston, Massachusetts, USA.
Article em En | MEDLINE | ID: mdl-39082114
ABSTRACT
Antipsychotic (AP) use has been associated to QT interval prolongation on the surface electrocardiogram (ECG). Our study aimed to determine the incidence of corrected QT (QTc) interval prolongation among patients admitted to a psychiatric hospitalization unit requiring AP treatment and to assess the relationship between administered dose and QTc interval changes. We enrolled 179 patients admitted to the Hospital Psiquiátrico Departamental Universitario del Valle in Cali, Colombia. ECGs were conducted upon admission, and again at 3 and 7 days postadmission. The QT interval was measured, and QTc interval correction was performed using Bazzet's formula. QTc interval prolongation at time points B or C was observed in 9.5% of patients. Clozapine was the most common AP associated with QTc interval prolongation (20.59%), followed by olanzapine (15.38%). The relative risk of QT interval prolongation with clozapine compared to haloperidol was 4.17 (95% confidence interval, 1.14-15.17, P = 0.02). AP use upon hospital admission was linked to early (within 3 days) QTc interval prolongation. Clozapine and olanzapine were associated with a greater increase in QTc interval compared to haloperidol, indicating a need for rigorous electrocardiographic monitoring with their use.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Int Clin Psychopharmacol / Int. clin. psychopharmacol / International clinical psychopharmacology Assunto da revista: PSICOFARMACOLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Colômbia País de publicação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Int Clin Psychopharmacol / Int. clin. psychopharmacol / International clinical psychopharmacology Assunto da revista: PSICOFARMACOLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Colômbia País de publicação: Reino Unido